<DOC>
	<DOCNO>NCT00249808</DOCNO>
	<brief_summary>Phase IIIb/IV , open-label , multi-centre study patient receive efalizumab 1mg/kg/week 12 week . At anytime first 12 week , non-responding worsening patient discontinue efalizumab enter 12-week treatment period approve antipsoriasis therapy . Objectives : - To establish safe psoriasis control moderate severe chronic plaque psoriasis efalizumab patient fail respond , contraindication , intolerant systemic therapy include cyclosporine , methotrexate PUVA . - To evaluate management psoriasis event namely rebound exacerbation , patient Efalizumab subsequent discontinuation</brief_summary>
	<brief_title>A Study Efalizumab Patients With Moderate Severe Chronic Psoriasis Who Have Failed , Have Contraindication , Are Intolerant Other Systemic Therapies</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Moderate severe plaque psoriasis patient fail respond , contraindication , intolerant systemic therapy include cyclosporine , methotrexate PUVA . OR 18 75 year old . For woman childbearing potential men whose partner become pregnant , use acceptable method contraception prevent pregnancy agreement continue practice acceptable method contraception duration participation study 3 month last dose efalizumab . Willingness hold sun exposure reasonably constant avoid use tan booth UV light source study . Have give write informed consent , prior studyrelated procedure part normal medical care , understand consent may withdraw patient time without prejudice future medical care . Discontinuation systemic psoriasis treatment prior commencement study drug . No washout period require agent prior start study receive first dose study drug ( efalizumab ) . Discontinuation biologic agent ( efalizumab ) 3 month prior receive first dose study drug ( efalizumab ) . Discontinuation PUVA , UVB treatment 28 day prior commencement receive first dose study drug ( efalizumab ) . Discontinuation investigational drug treatment 3 month prior study day 0 per washout requirement previous protocol . No primary vaccination ( e.g. , tetanus , booster , influenza vaccine ) least 14 day prior first dose study drug . Treatment regimens b blocker , ACE inhibitor , antimalarial drug , quinidine , interferon , lithium stable least 28 day prior first dose study drug ( efalizumab ) . The patient must willing able comply protocol requirement duration study . Guttate , erythrodermic , pustular psoriasis sole predominant form psoriasis . Patients previously efalizumab treatment withdrew due lack efficacy adverse event . If withdrawal due another nondrug reason ( vaccination , infection ) patient include study . History severe allergic anaphylactic reaction humanise monoclonal antibody . History ongoing uncontrolled bacterial , viral , fungal , atypical mycobacterial infection History opportunistic infection ( eg , systemic fungal infection , parasite ) Seropositivity human immunodeficiency virus ( HIV ) . Patients undergo mandatory test screening . Patients positive HIV exclude . Pregnancy breast feed . WBC count &lt; 4000/L &gt; 14,000/L . Patient history clinically significant thrombocytopenia , bleed disorder platelet count &lt; 100,000 cells/L . Seropositivity hepatitis B C virus . Patients undergo test screening . Patients positive hepatitis B antigen hepatitis C antibody exclude . History active tuberculosis ( TB ) currently undergo treatment TB within one year prior study day 0 . Chest Xray ( within 3 month prior SD0 ) require highrisk patient . Patients positive chest Xray exclude . Presence malignancy within past 5 year , include lymphoproliferative disorder . Patients history fully resolve basal cell squamous cell skin cancer may enrol . Hospital admission cardiac disease , stroke , pulmonary disease within last year . Any medical condition , judgment investigator , would jeopardize patient 's safety follow exposure study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Candidates systemic therapy psoriasis</keyword>
</DOC>